David A. Siegel Siga Technologies Inc Transaction History

Two Sigma Advisers, LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$5.23 - $8.42 $1.24 Million - $2 Million	-237,800 Reduced 95.16%	12,100 $69,000
Q4 2022 Feb 14, 2023	BUY	$7.29 - $10.14 $1.82 Million - $2.53 Million	249,900 New	249,900 $1.84 Million
Q2 2022 Aug 15, 2022	BUY	$6.5 - $13.68 $1.67 Million - $3.51 Million	256,300 New	256,300 $2.97 Million
Q1 2021 May 17, 2021	SELL	$6.3 - $7.71 $216,720 - $265,224	-34,400 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$6.39 - $7.76 $34,506 - $41,904	-5,400 Reduced 13.57%	34,400 $250,000
Q3 2020 Nov 16, 2020	BUY	$5.62 - $7.68 $223,676 - $305,664	39,800 New	39,800 $273,000
Q3 2019 Nov 14, 2019	SELL	$4.93 - $5.8 $52,751 - $62,060	-10,700 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$5.22 - $6.1 $43,326 - $50,630	-8,300 Reduced 43.68%	10,700 $61,000
Q1 2019 May 15, 2019	BUY	$5.66 - $7.89 $7,924 - $11,046	1,400 Added 7.95%	19,000 $114,000
Q4 2018 Feb 14, 2019	SELL	$4.77 - $7.9 $24,803 - $41,080	-5,200 Reduced 22.81%	17,600 $139,000
Q3 2018 Nov 14, 2018	BUY	$6.03 - $8.34 $137,484 - $190,152	22,800 New	22,800 $157,000

185

35.7M

873K

466K

Ticker SIGA
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 73,024,096
Market Cap $437M
Description
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla T...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.